最近の記事
- 2025/10/16
- AIDXプレシジョン患者がん移植システムによるゼブラフィッシュ創薬と個別化医療
- 2025/06/17
- 患者がん移植ゼブラフィッシュモデル(PDXZ)の臨床展開
- 2025/06/02
- ポドサイトパチー創薬スクリーニング
- 2025/04/23
- ポドサイトパチー治療薬スクリーニング
- 2025/04/10
- 患者がん移植ゼブラフィッシュモデル(PDXZ)の展開
- 2025/02/05
- ゼブラフィッシュによるoncocardionephrologyの展開
- 2025/01/01
- ゼブラフィッシュ創薬のグローバル展開
| 2025/10/22 |
|
AI-Driven Precision Patient-Derived Cancer Xenograft Zebrafish System Protocol
Kana Shinogi1,2, Akiyoshi Shimizu1,2, Aoi Mori1,2, Kanako Nishino1,2, Saori Matsuoka1,2,Yuki Satoda1,2, ◯Toshio Tanaka1,2 ( 1Department of Systems Pharmacology, Mie University Graduate School of Medicine,
2 Mie University Medical Zebrafish Research Center)
Since 2024, the clinical implementation of Patient-Derived Xenograft Zebrafish systems (PDXZ) has accelerated. For example, a validation study involving 55 colorectal cancer patients demonstrated that the PDXZ system predicted patient treatment response with 91% accuracy (Nature Communications 2024 Jun 5;15:4771). Furthermore, the XenoZ clinical trial (NCT03668418), led by Portugal's Champalimaud Foundation, is the world's first randomized trial involving 120 pancreatic and gastrointestinal cancer patients, with patient enrollment beginning in January 2025. Therefore, anticipating rapid progress toward future clinical implementation, we attempted to maximize accuracy by minimizing non-clinical variability factors in this PDXZ protocol, focusing on the following three points for personalized medical decision-making and drug discovery screening decisions: We report the development of: 1) a fully individualized system to support the complete automation of PDXZ expected globally by 2030, 2) AI-based quality control for zebrafish hosts, and 3) AI-based quality control for patient tumor transplantation.
関連リンク
関連ファイル
